New drug FORX-428 targets Hard-to-Treat cancers in early trial

NCT ID NCT07356453

Recruiting now Disease control Sponsor: FoRx Therapeutics AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. Participants must have already tried at least one standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Knight Cancer Institute
RECRUITING

Portland, Oregon, 97239, United States
NEXT - Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States
START - Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
START - San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Stanford University Medical Center
RECRUITING

Palo Alto, California, 94304, United States
University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States
University of Texas - MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Washington University St. Louis
RECRUITING

St Louis, Missouri, 63108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.